Cohort characteristics | Incidence of attrition per 100 person years (95% CI) | Mean survival duration in years (95% CI) | P value (log-rank) |
Total | 3.2 (2.7 to 3.7) | 14.1 (13.4 to 14.8) | |
Gender | |||
Male | 3.8 (31. to 4.6) | 13.2 (2.1 to 14.3) | 0.008 (6.9) |
Female | 2.5 (2 to 3.2) | 13.8 (13.1 to 14.4) | |
Age in years at enrolment | |||
≤5 | 2.5 (1.9 to 3.2) | 15.1 (14.2 to 16) | <0.001 (36.8) |
6–10 | 2.8 (2.2 to 3.6) | 11.7 (11.1 to 12.2) | |
>10 | 6.7 (5 to 8.9) | 8.4 (7.43 to 9) | |
Residence | 0.002 (9.8) | ||
Maekel | 2.7 (2.3 to 3.3) | 14.6 (13.8 to 15.4) | |
Outside Maekel | 4.6 (3.5 to 5.9) | 10.9 (10 to 11.7) | |
Disease stage at presentation | <0.001 (22) | ||
Early | 1.4 (0.9 to 2.1) | 15 (14.2 to 15.7) | |
Advanced | 3.9 (3.3 to 4.6) | 13.2 (12.3 to 14) | |
TB status | 0.2 (1.5) | ||
Symptomatic and under treatment | 3.1 (2.6 to 3.7) | 9.9 (6.9 to 12.8) | |
Not symptomatic | 6.5 (2.7 to 15.8) | 14 (13.3 to 14.8) | |
Haemoglobin | 0.004 (8.3) | ||
Anaemia | 2.2 (1.7 to 2.9) | 11.5 (11 to 12) | |
Normal | 3.7 (2.9 to 4.7) | 12.8 (12 to 13) | |
WAZ | 0.014 (6) | ||
WAZ ≥−2 | 2.1 (1.48 to 3.1) | 13 (12.4 to 13.7) | |
WAZ <−2 | 3.5 (2.8 to 4.4) | 12 (11.4 to 12.8) | |
HAZ | 0.019 (5.4) | ||
HAZ ≥−2 | 2.3 (1.7 to 3.2) | 14.9 (13.7 to 16) | |
HAZ <−2 | 3.5 (3 to 4.2) | 12.7 (12 to 13.4) | |
BAZ | <0.001 (12.4) | ||
BAZ ≥−2 | 2.4 (1.9 to 3) | 15 (14 to 15.9) | |
BAZ <−2 | 4.4 (3.5 to 5.5) | 12 (11 to 13) | |
Initial cART backbone | <0.001 (54.5) | ||
AZT+3TC | 2.3 (1.9 to 2.8) | 13.9 (13.4 to 14.5) | |
Other backbones | 7.1 (5.6 to 9) | 11.3 (9.8 to 12.8) | |
NNRTI | 0.9 (0.015) | ||
Efavirenz (EFV) | 3.2 (2.6 to 3.9) | 13 (12.3 to 13.7) | |
Nevirapin (NVP) | 3 (2.5 to 3.9) | 14.2 (13.3 to 15.2) | |
Current cART regimen | |||
First-line cART | 3.34 (2.8 to 3.9) | 12.9 (12.3 to 13.4) | 0.15 (2) |
Second-line cART | 2.2 (1.3 to 3.7) | 15.7 (14.3 to 17) | |
Adherence | 0.68 (0.16) | ||
Suboptimal adherence | 2.9 (1.9 to 4.3) | 12.6 (11.8 to 13.4) | |
No record | 3.2 (2.7 to 3.7) | 14.3 (13.6 to 15) | |
cART change | <0.001 (136) | ||
cART change | 1 (0.84 to 1.3) | 13.6 (13 to 14) | |
No cART change | 2 (1.7 to 2.5) | 7.5 (6.6 to 8.4) |
Comparisons of survival duration were performed by using the log-rank test and its p value.
Other backbones refer to tenofovir disoproxil fumarate+emtricitabine, abacavir+3TC or stavudine+3TC. Anaemia was defined as haemoglobin level <11 g/dL for children <5 years old, <11.5 g/dL for children 5–11.9 years old and <12 g/dL for children >12 years old.
AZT+3TC, zidovudine+lamivudine; BAZ, body mass index-for-age z-score; cART, combined antiretroviral therapy; HAZ, height-for-age z-score; NNRTI, non-nucleoside reverse transcriptase inhibitor; TB, tuberculosis; WAZ, weight-for-age z-score.